Comera Life Sciences Holdings, Inc. (CMRA) |
1.37 -0.04 (-2.84%)
|
01-27 15:59 |
Open: |
1.42 |
Pre. Close: |
1.41 |
High:
|
1.52 |
Low:
|
1.31 |
Volume:
|
237,880 |
Market Cap:
|
31(M) |
|
|
Technical analysis |
as of: 2023-01-27 4:43:26 PM |
Overall:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Target: |
Six months: 2.08 One year: 2.53 |
Support: |
Support1: 1.16 Support2: 0.97 |
Resistance: |
Resistance1: 1.78 Resistance2: 2.17 |
Pivot: |
1.5  |
Moving Average: |
MA(5): 1.38 MA(20): 1.44 
MA(100): 1.58 MA(250): 4.55  |
MACD: |
MACD(12,26): 0 Signal(9): 0  |
Stochastic oscillator: |
%K(14,3): 21.3 %D(3): 21.5  |
RSI: |
RSI(14): 47.3  |
52-week: |
High: 15.3 Low: 1.11 |
Average Vol(K): |
3-Month: 64 (K) 10-Days: 73 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CMRA ] has closed above bottom band by 25.8%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
1.52 - 1.53 |
1.53 - 1.54 |
Low:
|
1.29 - 1.3 |
1.3 - 1.31 |
Close:
|
1.36 - 1.37 |
1.37 - 1.38 |
|
Company Description |
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts. |
Headline News |
Wed, 11 Jan 2023 5 ways NOAA supported climate science and solutions in 2022 - National Oceanic and Atmospheric Administration
Mon, 09 Jan 2023 5 hot insider trades: Travelzoo, CarMax By Investing.com - Investing.com
Wed, 04 Jan 2023 Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules - Yahoo Finance
Wed, 28 Dec 2022 3D Motorsports Named Dunlop Race Tire Supplier For CMRA Events - RoadracingWorld.com
Wed, 07 Dec 2022 Climate Mapping for Resilience and Adaptation (CMRA) Portal - Government Technology
Wed, 05 Oct 2022 CMRA: Sneed Wins Formula One Race At Hallett - RoadracingWorld.com
|
Financial Analysis |
Price to Book Value: |
Underperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Outperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Underperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
0 (M) |
Shares Float |
0 (M) |
% Held by Insiders
|
7.24e+006 (%) |
% Held by Institutions
|
50.2 (%) |
Shares Short
|
605 (K) |
Shares Short P.Month
|
0 (K) |
Stock Financials |
EPS
|
-9.27e+006 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
0 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
-2 |
Return on Assets (ttm)
|
322.4 |
Return on Equity (ttm)
|
0 |
Qtrly Rev. Growth
|
403160 |
Gross Profit (p.s.)
|
0 |
Sales Per Share
|
0 |
EBITDA (p.s.)
|
0 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
0 (M) |
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
PE Ratio
|
-0.01 |
PEG Ratio
|
0 |
Price to Book value
|
0 |
Price to Sales
|
0 |
Price to Cash Flow
|
0 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
172990 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|